The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Clinicopathologic Re-Evaluation of 100 Malignant Fibrous Histiocytomas: Prognostic Relevance of Subclassification
Abstract
PURPOSE: Malignant fibrous histiocytoma (MFH) has been regarded as the most common soft tissue sarcoma (STS) in adults. Yet its true nature and the validity of this diagnostic concept have increasingly been questioned. Available data suggest that most patients with MFH can be subclassified into specific STS types, but the clinical relevance of such categorization has been argued. In a retrospective study, we reclassified 100 tumors of the extremity and trunk wall primarily diagnosed as MFH and analyzed the outcome. PATIENTS AND METHODS: Patients were adults (median age, 70 years; range, 32 to 94 years). The median tumor size was 8 cm (range, 1 to 30 cm), and the thigh was the most common tumor location (n = 31). Median follow-up was 8 years (range, 3 to 16 years). The overall 5-year metastasis-free survival rate was 0.64. The tumors were reanalyzed histologically, immunohistochemically, and, where available, ultrastructurally, and were classified according to strict diagnostic criteria. Patients were staged according to the American Joint Committee on Cancer system, and prognoses were compared among different groups of the reclassified diagnoses, paying special attention to myogenic tumors. RESULTS: In 84 of 100 tumors, a specific line of differentiation was either proved or strongly suggested. The most common diagnoses were myxofibrosarcoma (n = 22) and leiomyosarcoma (n = 20). Overall, 30 tumors could be grouped as some form of myogenic sarcoma. These tumors had a worse prognosis, even within the same American Joint Committee on Cancer stage, and a shorter time to metastasis than nonmyogenic tumors. CONCLUSION: This retrospective study confirms that most so-called MFH can be subclassified by defined criteria; it provides evidence that such classification is clinically important. Specifically, pleomorphic STS showing myogenic differentiation are significantly more aggressive, a finding that allows planning future therapeutic trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malignant fibrous histiocytoma.An Analysis of 200 Cases
Weiss, S. W., & Enzinger, F. M. (1978) · Cancer · doi:10.1002/1097-0142(197806)41:6<2250::aid-cncr2820410626>3.0.co;2-w · Cited by 1,500
Coindre, J. M., Terrier, P., Bui, N. B., Bonichon, F., Collin, F., Le Doussal, V, Mandard, A. M., Vilain, M. O., Jacquemier, J., Duplay, H., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.869 · Cited by 636
Henricks, W. H., Chu, Y. C., Goldblum, J. R., & Weiss, S. W. (1997) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199703000-00002 · Cited by 632
Myxofibrosarcoma: Clinicopathologic Analysis of 75 Cases with Emphasis on the Low-grade Variant
Mentzel, T., Calonje, E., Wadden, C., Camplejohn, R. S., Beham, A., Smith, M. A., & Fletcher, C. D. M. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199604000-00001 · Cited by 530
Self-citationFletcher, C. D. �. (1992) · PubMed · Cited by 400
Self-citationPleomorphic Malignant Fibrous Histiocytoma: Fact or Fiction?
Fletcher, C. D. M. (1992) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199203000-00001 · Cited by 381
Self-citationMcCormick, D., Mentzel, T., Beham, A., & Fletcher, C. D. M. (1994) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199412000-00004 · Cited by 324
Self-citationSoft tissue sarcoma: Epidemiology and prognosis in 508 patients
Gustafson, P. (1994) · Acta Orthopaedica Scandinavica · doi:10.3109/17453679409153928 · Cited by 253
Self-citationPrognostic Factors Predictive of Survival and Local Recurrence for Extremity Soft Tissue Sarcoma
Singer, S., Corson, J. M., Gonin, R., Labow, B., & Eberlein, T. J. (1994) · Annals of Surgery · doi:10.1097/00000658-199402000-00008 · Cited by 206
Mertens, F., Fletcher, C. D. M., Dal Cin, P., De Wever, I., Mandahl, N., Mitelman, F., Rosai, J., Rydholm, A., Sciot, R., Tallini, G., et al. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199805)22:1<16::aid-gcc3>3.0.co;2-a · Cited by 181
Self-citationJj, B. (1986) · PubMed Central · Cited by 154
Malignant fibrous histiocytoma?
Fletcher, C. D. �. (1987) · Histopathology · doi:10.1111/j.1365-2559.1987.tb02648.x · Cited by 76
Self-citationHashimoto, H., Daimaru, Y., Tsuneyoshi, M., & Enjoji, M. (1990) · Cancer · Cited by 57
Cited by
WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition
Jo, V. Y., & Fletcher, C. D. M. (2014) · Pathology · doi:10.1097/pat.0000000000000050 · Cited by 971
Self-citationMaki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Binh, M. B. N., Sastre-Garau, X., Guillou, L., Pinieux, G. D., Terrier, P., Lagacé, R., Aurias, A., Hostein, I., & Coindre, J. M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000170343.09562.39 · Cited by 639
Molecular characterisation of soft tissue tumours: a gene expression study
Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O'Connell, J. X., Zhu, S., Fero, M., Sherlock, G., Pollack, J. R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08270-3 · Cited by 576
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353
Metadata
- Authors
- Fletcher, C. D. M., Gustafson, P., Rydholm, A., Willén, H., & Åkerman, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-06-15
- Volume
- 19
- Issue
- 12
- Pages
- 3045-3050
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1880275688
- Cited by
- 355
- References
- 13
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.